The Technical Analyst
Galectin Therapeutics Inc [GALT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Galectin Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
6.38% $3.50
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 216.66 mill |
| EPS: | -0.740 |
| P/E: | -4.73 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 61.90 mill |
| Avg Daily Volume: | 0.150 mill |
| RATING 2024-04-25 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.73 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.80x |
| Company: PE -4.73 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.767 (-121.92%) $-4.27 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.28 - 3.72 ( +/- 6.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-24 | Lewis Joel | Buy | 1 000 | Common Stock |
| 2023-12-31 | Czirr James C | Buy | 0 | |
| 2024-04-22 | Czirr James C | Sell | 21 323 | Common Stock |
| 2024-04-23 | Czirr James C | Sell | 3 677 | Common Stock |
| 2024-04-22 | Freeman Kevin D | Buy | 2 500 | Common Stock |
| INSIDER POWER |
|---|
| 24.16 |
| Last 97 transactions |
| Buy: 4 256 891 | Sell: 2 389 317 |
Forecast:
16:00 - $3.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.48
Forecast 2: 16:00 - $3.48
Forecast 3: 16:00 - $3.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.50 (6.38% ) |
| Volume | 0.212 mill |
| Avg. Vol. | 0.150 mill |
| % of Avg. Vol | 140.85 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GALT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| SFRXETHUSD | Apr 26 - 00:19 | 3 390.47 |
| APE18876USD | Apr 26 - 00:19 | 1.255 |
| JOEUSD | Apr 26 - 00:18 | 0.539 |
| KASUSD | Apr 26 - 00:18 | 0.118 |
| SUIUSD | Apr 26 - 00:14 | 1.184 |
| TONUSD | Apr 26 - 00:13 | 5.33 |
| OHMUSD | Apr 26 - 00:13 | 12.16 |
| SWETHUSD | Apr 26 - 00:14 | 3 302.08 |
| NTRNUSD | Apr 26 - 00:14 | 0.756 |
| GFARM2USD | Apr 26 - 00:14 | 3 427.32 |
Latest Press Releases
2024-03-29 08:00:00 - Press Release
Galectin Therapeutics Reports 2023 Financial Results And Provides Business Update
Norcross, ga., march 29, 2024 (globe newswire) -- galectin therapeutics, inc. (nasdaq: galt), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended december 31, 2023.
2024-03-12 08:00:00 - Press Release
Galectin Therapeutics Expands Clinical Team With The Appointment Of Khurram Jamil, M.d. As Vice President, Clinical Development
Norcross, ga., march 12, 2024 (globe newswire) -- galectin therapeutics, inc. (nasdaq: galt), the leading developer of therapeutics that target galectin proteins, today announced the appointment of khurram jamil, m.d. as vice president, clinical development. dr. jamil brings to galectin almost two decades of experience in clinical development across the biotechnology industry.
2023-12-07 06:00:00 - Press Release
Puretech Presents Data From Phase 1 Trial Of Lyt-200 Targeting Galectin-9 In Solid Tumors At The Esmo Immuno-oncology Congress 2023
Boston--(business wire)--puretech presents data from phase 1 trial of lyt-200 targeting galectin-9 in solid tumors at the esmo immuno-oncology congress 2023.
2023-11-13 08:45:00 - Press Release
Update – Galectin Therapeutics Reports Financial Results For The Quarter Ended September 30, 2023 And Provides Business Update
Norcross, ga., nov. 13, 2023 (globe newswire) -- galectin therapeutics, inc. (nasdaq: galt), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended september 30, 2023. these results are included in the company's quarterly report on form 10-q, which has been filed with the u.s. securities and exchange commission and is available at www.sec.gov .
2023-11-13 08:00:00 - Press Release
Galectin Therapeutics Reports Financial Results For The Quarter Ended September 30, 2023 And Provides Business Update
Norcross, ga., nov. 13, 2023 (globe newswire) -- galectin therapeutics, inc. (nasdaq: galt), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended september 30, 2023. these results are included in the company's quarterly report on form 10-q, which has been filed with the u.s. securities and exchange commission and is available at www.sec.gov .
Latest News
2024-04-05 08:52:57 - InvestorPlace
GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023
Galectin Therapeutics (NASDAQ: GALT ) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents.
2024-03-20 20:11:22 - Seeking Alpha
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
Interim results from the phase 2b/3 NAVIGATE study, using Belapectin for the prevention of esophageal varices in NASH Cirrhosis patients, expected Q4 of 2024. In a prior phase 2 study, it was shown that Belapectin was effective in treating patients who had not yet developed esophageal varices. Global non-alcoholic steatohepatitis market is expected to grow to $14.53 billion by 2028; 20% will develop NASH Cirrhosis and then about half will not have esophageal varices.
2023-10-23 08:00:00 - GlobeNewsWire
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023.
2023-09-26 08:00:00 - GlobeNewsWire
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry's preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled “Targeting Activated Macrophages to Improve Liver Cirrhosis: The Discovery and Clinical Translation of Belapectin,” will take place Wednesday, September 27, at 2:25 PM EDT and will be delivered by Dr. Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.
2023-09-14 08:15:00 - Seeking Alpha
Galecto Biotech Collapse: Opportunity For Galectin Therapeutics
Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative clinical outcomes. Galectin Therapeutics' belapectin, a galectin-3 inhibitor in a phase 3 trial for NASH cirrhosis, is a better value proposition with a strong financial backer and excellent safety profile.
2023-09-13 17:22:00 - GlobeNewsWire
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York – brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.
2023-09-11 08:00:00 - GlobeNewsWire
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York – brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.
2023-09-07 12:00:00 - GlobeNewsWire
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research developments in non-alcoholic steatohepatitis (NASH) and its complications, including liver cirrhosis. This year, Galectin Therapeutics, in collaboration with HistoIndex of Singapore, will present a poster on the use of artificial intelligence to better explore the complex histology of liver cirrhosis resulting from NASH and highlight potential differences between lean cirrhotic patients and overweight/obese cirrhotic patients...
2023-08-17 13:17:17 - Zacks Investment Research
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
Galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-05-18 16:37:15 - InvestorPlace
7 Short-Interest Stocks to Target for Explosive Gains
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks.